Last Updated : April 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Received | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Received | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Received | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
N/A | imiquimod | Gynecological cancers | Withdrawn | |||
Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
Olumiant | baricitinib | Alopecia areata, severe | Active | |||
Veklury | remdesivir | COVID-19 in hospitalized patients | Active |